Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2012. The report details a specific corporate action regarding share repurchases executed on May 21, 2012, following shareholder authorization at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,800,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,411.5 pence per share; lowest price paid was 1,400.0 pence per share.
- Treasury Holdings (Settled): 532,947,927 shares (9.58% of total issued share capital).
- Treasury Holdings (Including Unsettled): 537,947,927 shares (10.69% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,031,718,012 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 1,800,000 shares. This transaction increased the company's treasury holdings, raising the percentage of total voting rights held in treasury to 10.69% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (532,947,927 settled) against the company's latest capitalization table.
- Confirm the impact of the 10.69% treasury holding on total voting rights calculations for major shareholders.
- Check subsequent filings to determine if the remaining authorized share buyback program has been fully utilized.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or interim results for revenue and profit metrics.